Federal Register Final rule: FDA is amending the standing advisory committees’ regulations to change the name and function of the Advisory Committee for Reproductive Health Drugs to “Bone, Reproductive and Urologic Drugs Advisory Committee.” The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drug products for use in the practice of osteoporosis and metabolic bone disease, obstetrics, gynecology, urology and related specialties, and makes appropriate recommendations to the FDA Commissioner. To view this final rule, click here.